INADVERTENT INTRATHECAL USE OF OMNISCAN HAS CAUSED CONVULSIONS, COMA, SENSORY AND MOTOR NEUROLOGIC DEFICITS. IT INCREASES THE RISK FOR NSF (NEPHROGENIC SYSTEMIC FIBROSIS) IN PATIENTS WITH: ACUTE OR CHRONIC SEVERE RENAL INSUFFICIENCY (GLOMERULAR FILTRATION RATE < 30 ML/MIN/1.73M2), OR ACUTE RENAL INSUFFICIENCY OF ANY SEVERITY DUE TO THE HEPATO-RENAL SYNDROME OR IN THE PERIOPERATIVE LIVER TRANSPLANTATION PERIOD.
CNS (CENTRAL NERVOUS SYSTEM)
ADULTS: 0.2 ML/KG (0.1 MMOL/KG) ADMINISTERED AS A BOLUS INTRAVENOUS INJECTION. AN ADDITIONAL 0.4 ML/KG (0.2 MMOL/KG) CAN BE GIVEN WITHIN 20 MINUTES OF THE FIRST DOSE.
PEDIATRIC PATIENTS (2-16 YEARS): 0.2 ML/KG (0.1 MMOL/KG) ADMINISTERED AS A BOLUS INTRAVENOUS INJECTION.
BODY (INTRATHORACIC [NONCARDIAC], INTRA-ABDOMINAL, PELVIC AND RETROPERITONEAL REGIONS):
ADULT AND PEDIATRIC PATIENTS (2-16 YEARS OF AGE): FOR IMAGING THE KIDNEY, THE RECOMMENDED DOSE OF OMNISCAN IS 0.1 ML/KG (0.05 MMOL/KG). FOR IMAGING THE INTRATHORACIC (NONCARDIAC), INTRA-ABDOMINAL, AND PELVIC CAVITIES, THE RECOMMENDED DOSE OF OMNISCAN IS 0.2 ML/KG (0.1 MMOL/KG).
DETAILED DOSING CAN BE SEEN IN THE MONOGRAPH.